Replicating adenovirus vector prime/protein boost strategies for HIV vaccine development (Q56993265)

https://api.crossref.org/works/10.1517%2F14712598.8.9.1347

HIV vaccines: new frontiers in vaccine development

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.8.9.1347

Viral load and heterosexual transmission of human immunodeficiency virus type 1. Rakai Project Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.8.9.1347

Human immunodeficiency virus controllers: mechanisms of durable virus control in the absence of antiretroviral therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.8.9.1347

Severe depletion of mucosal CD4+ T cells in AIDS-free simian immunodeficiency virus-infected sooty mangabeys

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.8.9.1347

Acute loss of intestinal CD4+ T cells is not predictive of simian immunodeficiency virus virulence

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.8.9.1347

An HIV vaccine--evolving concepts

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.8.9.1347

Preserved CD4+ central memory T cells and survival in vaccinated SIV-challenged monkeys

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.8.9.1347

Immunization with a modified vaccinia virus expressing simian immunodeficiency virus (SIV) Gag-Pol primes for an anamnestic Gag-specific cytotoxic T-lymphocyte response and is associated with reduction of viremia after SIV challenge

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.8.9.1347

Replication-incompetent adenoviral vaccine vector elicits effective anti-immunodeficiency-virus immunity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.8.9.1347

Control of viremia in simian immunodeficiency virus infection by CD8+ lymphocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.8.9.1347

Human neutralizing monoclonal antibodies of the IgG1 subtype protect against mucosal simian-human immunodeficiency virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.8.9.1347

Protection of macaques against vaginal transmission of a pathogenic HIV-1/SIV chimeric virus by passive infusion of neutralizing antibodies

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.8.9.1347

Antibody protects macaques against vaginal challenge with a pathogenic R5 simian/human immunodeficiency virus at serum levels giving complete neutralization in vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.8.9.1347

Broad HIV-1 neutralization mediated by CD4-binding site antibodies

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.8.9.1347

Massive infection and loss of memory CD4+ T cells in multiple tissues during acute SIV infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.8.9.1347

Identifying the target cell in primary simian immunodeficiency virus (SIV) infection: highly activated memory CD4(+) T cells are rapidly eliminated in early SIV infection in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.8.9.1347

Pathogenesis of HIV infection: what the virus spares is as important as what it destroys

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.8.9.1347

HIV disease: fallout from a mucosal catastrophe?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.8.9.1347

Protective effects of a live attenuated SIV vaccine with a deletion in the nef gene

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.8.9.1347

Pathogenicity of live, attenuated SIV after mucosal infection of neonatal macaques

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.8.9.1347

Vaccines for mucosal immunity to combat emerging infectious diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.8.9.1347

Live attenuated HIV vaccines: pitfalls and prospects

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.8.9.1347

Rapid appearance of secondary immune responses and protection from acute CD4 depletion after a highly pathogenic immunodeficiency virus challenge in macaques vaccinated with a DNA prime/Sendai virus vector boost regimen

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.8.9.1347

Poliovirus vaccine strains as mucosal vaccine vectors and their potential use to develop an AIDS vaccine.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.8.9.1347

Use of viral vectors for the development of vaccines

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.8.9.1347

Current overview of the pathogenesis and prophylaxis of measles with focus on practical implications

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.8.9.1347

Attenuated measles virus as a vaccine vector

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.8.9.1347

A single injection of recombinant measles virus vaccines expressing human immunodeficiency virus (HIV) type 1 clade B envelope glycoproteins induces neutralizing antibodies and cellular immune responses to HIV.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.8.9.1347

Live measles vaccine expressing the secreted form of the West Nile virus envelope glycoprotein protects against West Nile virus encephalitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.8.9.1347

Response to different measles vaccine strains given by aerosol and subcutaneous routes to schoolchildren: a randomised trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.8.9.1347

Recombinant vesicular stomatitis viruses from DNA.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.8.9.1347

An effective AIDS vaccine based on live attenuated vesicular stomatitis virus recombinants

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.8.9.1347

A single-cycle vaccine vector based on vesicular stomatitis virus can induce immune responses comparable to those generated by a replication-competent vector

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.8.9.1347

Immunogenicity of attenuated vesicular stomatitis virus vectors expressing HIV type 1 Env and SIV Gag proteins: comparison of intranasal and intramuscular vaccination routes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.8.9.1347

Viral replication in olfactory receptor neurons and entry into the olfactory bulb and brain

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.8.9.1347

Neurovirulence properties of recombinant vesicular stomatitis virus vectors in non-human primates

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.8.9.1347

Generation of packaging cell lines for pseudotyped retroviral vectors of the G protein of vesicular stomatitis virus by using a modified tetracycline inducible system

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.8.9.1347

Priming with plasmid DNAs expressing interleukin-12 and simian immunodeficiency virus gag enhances the immunogenicity and efficacy of an experimental AIDS vaccine based on recombinant vesicular stomatitis virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.8.9.1347

Long-term safety analysis of preventive HIV-1 vaccines evaluated in AIDS vaccine evaluation group NIAID-sponsored Phase I and II clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.8.9.1347

Safety of and immunological response to a recombinant vaccinia virus vaccine expressing HIV envelope glycoprotein

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.8.9.1347

Recombinant Virus Vaccine-Induced SIV-specific CD8 + Cytotoxic T Lymphocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.8.9.1347

Vaccination of vaccinia-naive adults with human immunodeficiency virus type 1 gp160 recombinant vaccinia virus in a blinded, controlled, randomized clinical trial. The AIDS Vaccine Clinical Trials Network

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.8.9.1347

Disseminated vaccinia in a military recruit with human immunodeficiency virus (HIV) disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.8.9.1347

A call for replicating vector prime-protein boost strategies in HIV vaccine design

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.8.9.1347

Replicating and non-replicating viral vectors for vaccine development

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.8.9.1347

Dendritic cells and the control of immunity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.8.9.1347

Latent adenoviral infection in the pathogenesis of chronic airways obstruction

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.8.9.1347

Immunization by selective infection with type 4 adenovirus grown in human diploid tissue culture. II. specific protective effect against epidemic disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.8.9.1347

Characteristics of vaccine-induced and natural infection with adenovirus type 4 in naval recruits

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.8.9.1347

Communicability of enteric live adenovirus type 4 vaccine in families.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.8.9.1347

Experimental infections of humans with wild-type adenoviruses and with replication-competent adenovirus vectors: replication, safety, and transmission

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.8.9.1347

Immunogenicity and efficacy testing in chimpanzees of an oral hepatitis B vaccine based on live recombinant adenovirus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.8.9.1347

Replication and immunogenicity of Ad7-, Ad4-, and Ad5-hepatitis B virus surface antigen recombinants, with or without a portion of E3 region, in chimpanzees

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.8.9.1347

Adenovirus-human immunodeficiency virus (HIV) envelope recombinant vaccines elicit high-titered HIV-neutralizing antibodies in the dog model

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.8.9.1347

Immunogenicity of recombinant adenovirus-human immunodeficiency virus vaccines in chimpanzees following intranasal administration

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.8.9.1347

Long-term protection of chimpanzees against high-dose HIV-1 challenge induced by immunization

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.8.9.1347

Control of a mucosal challenge and prevention of AIDS by a multiprotein DNA/MVA vaccine.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.8.9.1347

Naturally occurring V1-env region variants mediate simian immunodeficiency virus SIVmac escape from high-titer neutralizing antibodies induced by a protective subunit vaccine

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.8.9.1347

Boosting of SIV-specific immune responses in rhesus macaques by repeated administration of Ad5hr-SIVenv/rev and Ad5hr-SIVgag recombinants

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.8.9.1347

Improved protection of rhesus macaques against intrarectal simian immunodeficiency virus SIV(mac251) challenge by a replication-competent Ad5hr-SIVenv/rev and Ad5hr-SIVgag recombinant priming/gp120 boosting regimen

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.8.9.1347

Potent, persistent cellular immune responses elicited by sequential immunization of rhesus macaques with Ad5 host range mutant recombinants encoding SIV Rev and SIV Nef.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.8.9.1347

A synthetic conformational epitope from the C4 domain of HIV Gp120 that binds CD4.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.8.9.1347

Potent, persistent induction and modulation of cellular immune responses in rhesus macaques primed with Ad5hr-simian immunodeficiency virus (SIV) env/rev, gag, and/or nef vaccines and boosted with SIV gp120.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.8.9.1347

Protection against mucosal simian immunodeficiency virus SIV(mac251) challenge by using replicating adenovirus-SIV multigene vaccine priming and subunit boosting

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.8.9.1347

Fc receptor but not complement binding is important in antibody protection against HIV.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.8.9.1347

Comparative evaluation of oral and intranasal priming with replication-competent adenovirus 5 host range mutant (Ad5hr)-simian immunodeficiency virus (SIV) recombinant vaccines on immunogenicity and protective efficacy against SIV(mac251).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.8.9.1347

Vaccination with DNA containing tat coding sequences and unmethylated CpG motifs protects cynomolgus monkeys upon infection with simian/human immunodeficiency virus (SHIV89.6P).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.8.9.1347

A replication-competent adenovirus-human immunodeficiency virus (Ad-HIV) tat and Ad-HIV env priming/Tat and envelope protein boosting regimen elicits enhanced protective efficacy against simian/human immunodeficiency virus SHIV89.6P challenge in rhe

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.8.9.1347

Native HIV-1 Tat protein targets monocyte-derived dendritic cells and enhances their maturation, function, and antigen-specific T cell responses

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.8.9.1347

Tat-mediated protein delivery can facilitate MHC class I presentation of antigens

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.8.9.1347

Efficient protein boosting after plasmid DNA or recombinant adenovirus immunization with HIV-1 vaccine constructs

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.8.9.1347

Phase 2 study of an HIV-1 canarypox vaccine (vCP1452) alone and in combination with rgp120: negative results fail to trigger a phase 3 correlates trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.8.9.1347

Heterologous prime/boost immunization of rhesus monkeys by using diverse poxvirus vectors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.8.9.1347

An HIV-1 clade C DNA prime, NYVAC boost vaccine regimen induces reliable, polyfunctional, and long-lasting T cell responses

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.8.9.1347

Prime-boost vaccination with HIV-1 Gag protein and cytosine phosphate guanosine oligodeoxynucleotide, followed by adenovirus, induces sustained and robust humoral and cellular immune responses

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.8.9.1347

Replicating rather than nonreplicating adenovirus-human immunodeficiency virus recombinant vaccines are better at eliciting potent cellular immunity and priming high-titer antibodies

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.8.9.1347

An adenovirus-based HIV subtype B prime/boost vaccine regimen elicits antibodies mediating broad antibody-dependent cellular cytotoxicity against non-subtype B HIV strains.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.8.9.1347

Comparative seroprevalence and immunogenicity of six rare serotype recombinant adenovirus vaccine vectors from subgroups B and D

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.8.9.1347

Effect of preexisting immunity to adenovirus human serotype 5 antigens on the immune responses of nonhuman primates to vaccine regimens based on human- or chimpanzee-derived adenovirus vectors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.8.9.1347

Adenovirus types 5 and 35 seroprevalence in AIDS risk groups supports type 35 as a vaccine vector

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.8.9.1347

Vectored Gag and Env but not Tat show efficacy against simian-human immunodeficiency virus 89.6P challenge in Mamu-A*01-negative rhesus monkeys

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.8.9.1347

Attenuation of simian immunodeficiency virus SIVmac239 infection by prophylactic immunization with dna and recombinant adenoviral vaccine vectors expressing Gag

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.8.9.1347

Phase 1 safety and immunogenicity evaluation of a multiclade HIV-1 candidate vaccine delivered by a replication-defective recombinant adenovirus vector

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.8.9.1347

Phase 1 safety and immunogenicity evaluation of a multiclade HIV-1 DNA candidate vaccine

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.8.9.1347

Immunogenicity of recombinant human adenovirus-human immunodeficiency virus vaccines in chimpanzees

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.8.9.1347

Experimental respiratory infection with type 4 adenovirus vaccine in volunteers: clinical and immunological responses

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.8.9.1347

Immunization with live type 4 adenovirus: determination of infectious virus dose and protective effect of enteric infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.8.9.1347

Oral delivery of replication-competent adenovirus vectors is well tolerated by SIV- and SHIV-infected rhesus macaques.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.8.9.1347

Prevalence of antibodies to adenovirus serotypes 4 and 7 among unimmunized US Army trainees: results of a retrospective nationwide seroprevalence survey

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.8.9.1347

Traitors of the immune system-enhancing antibodies in HIV infection: their possible implication in HIV vaccine development

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.8.9.1347

Simian immunodeficiency virus SIVagm.sab infection of Caribbean African green monkeys: a new model for the study of SIV pathogenesis in natural hosts

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.8.9.1347

Drug evaluation: DNA/MVA prime-boost HIV vaccine

21 January 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2538611

Peak SIV replication in resting memory CD4+ T cells depletes gut lamina propria CD4+ T cells.

2 November 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2538611

Aerosolized measles and measles-rubella vaccines induce better measles antibody booster responses than injected vaccines: randomized trials in Mexican schoolchildren

2 November 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2538611

Protection by live, attenuated simian immunodeficiency virus against heterologous challenge.

2 November 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2538611

Factors associated with slow disease progression in macaques immunized with an adenovirus-simian immunodeficiency virus (SIV) envelope priming-gp120 boosting regimen and challenged vaginally with SIVmac251.

2 November 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2538611

A recombinant measles virus expressing hepatitis B virus surface antigen induces humoral immune responses in genetically modified mice.

2 November 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2538611

Protection of Macaques against pathogenic simian/human immunodeficiency virus 89.6PD by passive transfer of neutralizing antibodies.

2 November 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2538611

Attenuated vesicular stomatitis viruses as vaccine vectors

2 November 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2538611

Live attenuated, multiply deleted simian immunodeficiency virus causes AIDS in infant and adult macaques

2 November 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2538611

Vaccine protection against a heterologous, non-syncytium-inducing, primary human immunodeficiency virus.

2 November 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2538611

Vaccination with a recombinant vesicular stomatitis virus expressing an influenza virus hemagglutinin provides complete protection from influenza virus challenge

2 November 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2538611

Induction of neutralizing antibodies to T-cell line-adapted and primary human immunodeficiency virus type 1 isolates with a prime-boost vaccine regimen in chimpanzees.

2 November 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2538611

An adenovirus-simian immunodeficiency virus env vaccine elicits humoral, cellular, and mucosal immune responses in rhesus macaques and decreases viral burden following vaginal challenge

2 November 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2538611

Inactivation of the human immunodeficiency virus type 1 inhibitory elements allows Rev-independent expression of Gag and Gag/protease and particle formation

2 November 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2538611

Resistance of neonatal monkeys to live attenuated vaccine strains of simian immunodeficiency virus

2 November 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2538611

Repair and evolution of nef in vivo modulates simian immunodeficiency virus virulence

2 November 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2538611

Relationship of adenovirus to lymphocytes in naturally infected human tonsils and adenoids

2 November 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2538611

Mutational inactivation of an inhibitory sequence in human immunodeficiency virus type 1 results in Rev-independent gag expression

2 November 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2538611

Coexpression of the simian immunodeficiency virus Env and Rev proteins by a recombinant human adenovirus host range mutant

2 November 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2538611

Ecological Associations of Vesicular Stomatitis Virus in Rural Central America and Panama *

2 November 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2538611

Enhanced cellular immunity to SIV Gag following co-administration of adenoviruses encoding wild-type or mutant HIV Tat and SIV Gag

2 November 2018

1 reference

12 December 2020

Preclinical evaluation of cellular immune responses elicited by a polyvalent DNA prime/protein boost HIV-1 vaccine

1 reference

12 December 2020

Initial safety and immunogenicity studies of an oral recombinant adenohepatitis B vaccine

1 reference

12 December 2020

Adenovirus Vaccines in the U.S. Military

1 reference

12 December 2020

A Helical Epitope in the C4 Domain of HIV Glycoprotein 120

1 reference

12 December 2020

AIDS research. Promising AIDS vaccine's failure leaves field reeling

1 reference

12 December 2020

Control of viremia and prevention of clinical AIDS in rhesus monkeys by cytokine-augmented DNA vaccination

1 reference

12 December 2020

Recombinant measles viruses expressing heterologous antigens of mumps and simian immunodeficiency viruses

1 reference

12 December 2020

Durable protection of rhesus macaques immunized with a replicating adenovirus-SIV multigene prime/protein boost vaccine regimen against a second SIVmac251 rectal challenge: role of SIV-specific CD8+ T cell responses

1 reference

12 December 2020

Replicating adenovirus HIV/SIV recombinant priming alone or in combination with a gp140 protein boost results in significant control of viremia following a SHIV89.6P challenge in Mamu-A*01 negative rhesus macaques

1 reference

12 December 2020

Immune response to HIV-1 gag antigens induced by recombinant adenovirus vectors in mice and rhesus macaque monkeys

1 reference

12 December 2020

A replication competent adenovirus 5 host range mutant-simian immunodeficiency virus (SIV) recombinant priming/subunit protein boosting vaccine regimen induces broad, persistent SIV-specific cellular immunity to dominant and subdominant epitopes in M

1 reference

12 December 2020

Immunization by selective infection with type 4 adenovirus grown in human diploid tissue cultures. I. Safety and lack of oncogenicity and tests for potency in volunteers

1 reference

12 December 2020

Spread of enteric live adenovirus type 4 vaccine in married couples

1 reference

12 December 2020

Control of SHIV-89.6P-infection of cynomolgus monkeys by HIV-1 Tat protein vaccine

1 reference

12 December 2020

Vaccine-elicited antibodies mediate antibody-dependent cellular cytotoxicity correlated with significantly reduced acute viremia in rhesus macaques challenged with SIVmac251

1 reference

12 December 2020